28.61 USD
+0.42 (+1.49%)
28.61 USD
0 (0%)
Overall ALKS gets a fundamental rating of 6 out of 10. We evaluated ALKS against 533 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making ALKS a very profitable company, without any liquidiy or solvency issues. ALKS has a decent growth rate and is not valued too expensively. These ratings would make ALKS suitable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year ALKS was profitable.
In the past year ALKS had a positive cash flow from operations.
In multiple years ALKS reported negative net income over the last 5 years.
Each year in the past 5 years ALKS had a positive operating cash flow.
1.2 Ratios
The Return On Assets of ALKS (14.57%) is better than 95.12% of its industry peers.
The Return On Equity of ALKS (19.58%) is better than 95.87% of its industry peers.
With an excellent Return On Invested Capital value of 16.22%, ALKS belongs to the best of the industry, outperforming 96.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.57% | ||
| ROE | 19.58% | ||
| ROIC | 16.22% |
ROA(3y)8.82%
ROA(5y)3.68%
ROE(3y)13.16%
ROE(5y)4.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALKS's Profit Margin of 22.30% is amongst the best of the industry. ALKS outperforms 94.75% of its industry peers.
ALKS's Operating Margin of 23.59% is amongst the best of the industry. ALKS outperforms 95.68% of its industry peers.
The Gross Margin of ALKS (86.04%) is better than 87.99% of its industry peers.
ALKS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.59% | ||
| PM (TTM) | 22.3% | ||
| GM | 86.04% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5Y-0.08%
2. Health
2.1 Basic Checks
ALKS has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
ALKS has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALKS has more shares outstanding
ALKS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ALKS has an Altman-Z score of 6.10. This indicates that ALKS is financially healthy and has little risk of bankruptcy at the moment.
ALKS has a Altman-Z score of 6.10. This is in the better half of the industry: ALKS outperforms 77.11% of its industry peers.
There is no outstanding debt for ALKS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.1 |
ROIC/WACC2.11
WACC7.68%
2.3 Liquidity
ALKS has a Current Ratio of 3.67. This indicates that ALKS is financially healthy and has no problem in meeting its short term obligations.
ALKS has a Current ratio of 3.67. This is comparable to the rest of the industry: ALKS outperforms 45.22% of its industry peers.
A Quick Ratio of 3.27 indicates that ALKS has no problem at all paying its short term obligations.
ALKS has a Quick ratio (3.27) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.67 | ||
| Quick Ratio | 3.27 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 19.71% over the past year.
The Earnings Per Share has been growing by 32.50% on average over the past years. This is a very strong growth
Looking at the last year, ALKS shows a small growth in Revenue. The Revenue has grown by 1.08% in the last year.
ALKS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.87% yearly.
EPS 1Y (TTM)19.71%
EPS 3Y54.92%
EPS 5Y32.5%
EPS Q2Q%-31.94%
Revenue 1Y (TTM)1.08%
Revenue growth 3Y9.89%
Revenue growth 5Y5.87%
Sales Q2Q%4.24%
3.2 Future
The Earnings Per Share is expected to decrease by -4.73% on average over the next years.
ALKS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.56% yearly.
EPS Next Y-48.02%
EPS Next 2Y-31.39%
EPS Next 3Y-19.38%
EPS Next 5Y-4.73%
Revenue Next Year-2.6%
Revenue Next 2Y10.16%
Revenue Next 3Y6.82%
Revenue Next 5Y8.56%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 11.54, which indicates a very decent valuation of ALKS.
ALKS's Price/Earnings ratio is rather cheap when compared to the industry. ALKS is cheaper than 96.62% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.47. ALKS is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 20.96 indicates a rather expensive valuation of ALKS.
Based on the Price/Forward Earnings ratio, ALKS is valued cheaply inside the industry as 92.87% of the companies are valued more expensively.
ALKS's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 34.42.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.54 | ||
| Fwd PE | 20.96 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ALKS is valued cheaper than 97.56% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ALKS is valued cheaper than 98.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.61 | ||
| EV/EBITDA | 8.01 |
4.3 Compensation for Growth
ALKS has a very decent profitability rating, which may justify a higher PE ratio.
ALKS's earnings are expected to decrease with -19.38% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)0.35
EPS Next 2Y-31.39%
EPS Next 3Y-19.38%
5. Dividend
5.1 Amount
No dividends for ALKS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
28.61
+0.42 (+1.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners104.46%
Inst Owner Change8.97%
Ins Owners1.66%
Ins Owner Change1.24%
Market Cap4.72B
Revenue(TTM)1.52B
Net Income(TTM)339.32M
Analysts80.91
Price Target44.43 (55.3%)
Short Float %9.85%
Short Ratio6.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)66.1%
Min EPS beat(2)59.84%
Max EPS beat(2)72.36%
EPS beat(4)4
Avg EPS beat(4)43.68%
Min EPS beat(4)12.02%
Max EPS beat(4)72.36%
EPS beat(8)4
Avg EPS beat(8)10.27%
EPS beat(12)8
Avg EPS beat(12)42.89%
EPS beat(16)11
Avg EPS beat(16)151.46%
Revenue beat(2)2
Avg Revenue beat(2)10.32%
Min Revenue beat(2)8.51%
Max Revenue beat(2)12.13%
Revenue beat(4)3
Avg Revenue beat(4)7.62%
Min Revenue beat(4)-1.19%
Max Revenue beat(4)12.13%
Revenue beat(8)4
Avg Revenue beat(8)3.11%
Revenue beat(12)7
Avg Revenue beat(12)3.8%
Revenue beat(16)10
Avg Revenue beat(16)3.09%
PT rev (1m)3.41%
PT rev (3m)3.72%
EPS NQ rev (1m)3.07%
EPS NQ rev (3m)0.56%
EPS NY rev (1m)16.08%
EPS NY rev (3m)17.59%
Revenue NQ rev (1m)2.95%
Revenue NQ rev (3m)2.45%
Revenue NY rev (1m)3.24%
Revenue NY rev (3m)3.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.54 | ||
| Fwd PE | 20.96 | ||
| P/S | 3.1 | ||
| P/FCF | 9.61 | ||
| P/OCF | 8.74 | ||
| P/B | 2.72 | ||
| P/tB | 2.86 | ||
| EV/EBITDA | 8.01 |
EPS(TTM)2.48
EY8.67%
EPS(NY)1.37
Fwd EY4.77%
FCF(TTM)2.98
FCFY10.4%
OCF(TTM)3.28
OCFY11.45%
SpS9.22
BVpS10.5
TBVpS9.99
PEG (NY)N/A
PEG (5Y)0.35
Graham Number24.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.57% | ||
| ROE | 19.58% | ||
| ROCE | 19.34% | ||
| ROIC | 16.22% | ||
| ROICexc | 40.45% | ||
| ROICexgc | 45.58% | ||
| OM | 23.59% | ||
| PM (TTM) | 22.3% | ||
| GM | 86.04% | ||
| FCFM | 32.29% |
ROA(3y)8.82%
ROA(5y)3.68%
ROE(3y)13.16%
ROE(5y)4.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5Y-0.08%
F-Score6
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 163.07% | ||
| Cap/Sales | 3.25% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 138.93% | ||
| Profit Quality | 144.77% | ||
| Current Ratio | 3.67 | ||
| Quick Ratio | 3.27 | ||
| Altman-Z | 6.1 |
F-Score6
WACC7.68%
ROIC/WACC2.11
Cap/Depr(3y)76.88%
Cap/Depr(5y)63.55%
Cap/Sales(3y)2.83%
Cap/Sales(5y)2.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.71%
EPS 3Y54.92%
EPS 5Y32.5%
EPS Q2Q%-31.94%
EPS Next Y-48.02%
EPS Next 2Y-31.39%
EPS Next 3Y-19.38%
EPS Next 5Y-4.73%
Revenue 1Y (TTM)1.08%
Revenue growth 3Y9.89%
Revenue growth 5Y5.87%
Sales Q2Q%4.24%
Revenue Next Year-2.6%
Revenue Next 2Y10.16%
Revenue Next 3Y6.82%
Revenue Next 5Y8.56%
EBIT growth 1Y-17.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.49%
EBIT Next 3Y-3.56%
EBIT Next 5Y16.39%
FCF growth 1Y93.4%
FCF growth 3Y76.56%
FCF growth 5YN/A
OCF growth 1Y83.22%
OCF growth 3Y62.84%
OCF growth 5Y43.53%
ALKERMES PLC / ALKS FAQ
What is the fundamental rating for ALKS stock?
ChartMill assigns a fundamental rating of 6 / 10 to ALKS.
What is the valuation status for ALKS stock?
ChartMill assigns a valuation rating of 6 / 10 to ALKERMES PLC (ALKS). This can be considered as Fairly Valued.
Can you provide the profitability details for ALKERMES PLC?
ALKERMES PLC (ALKS) has a profitability rating of 7 / 10.
What is the valuation of ALKERMES PLC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ALKERMES PLC (ALKS) is 11.54 and the Price/Book (PB) ratio is 2.72.
What is the expected EPS growth for ALKERMES PLC (ALKS) stock?
The Earnings per Share (EPS) of ALKERMES PLC (ALKS) is expected to decline by -48.02% in the next year.